📖 Introduction
Glioblastoma (GBM) is the most aggressive and lethal primary brain tumor in adults. Despite surgery, radiotherapy, and chemotherapy, the median survival remains only 12–15 months. One of the major therapeutic challenges is the blood–brain barrier (BBB), which restricts drug delivery to brain tissue.
Signal Transducer and Activator of Transcription 3 (STAT3) is a key oncogenic transcription factor highly activated in glioblastoma. STAT3 promotes tumor growth, survival, invasion, angiogenesis, and therapy resistance. Targeted silencing of STAT3 using small interfering RNA (siRNA) represents a promising precision medicine strategy.
🎯 Objective
This study aimed to develop a novel exosome-based nano delivery platform capable of:
Efficient STAT3-siRNA delivery
Enhanced stability and uptake
Overcoming BBB limitations
Reducing tumor growth
Improving survival in a glioblastoma mouse model
The system combines Exosomes with Nano Lipid Particles (NLP-EXOSOME COMPLEX).
🧪 Materials & Methods
🔬 Nanoformulation Development
Isolation of exosomes from U87MG glioblastoma cells
Loading STAT3-targeted siRNA
Complexation with ionizable lipid nanoparticles via microfluidics
Characterization using TEM, DLS, and zeta potential analysis
🧫 In Vitro Studies
STAT3 mRNA quantification (qRT-PCR)
Protein analysis (Western blot)
Cytotoxicity assays (LDH, CCK-8)
Apoptosis analysis (flow cytometry)
Cell proliferation assessment
🐁 In Vivo Mouse Model
Intracranial tumor implantation
NLP-EXOSOME COMPLEX treatment
MRI tumor volume monitoring
Kaplan–Meier survival analysis
Laser microdissection and gene expression validation
📊 Key Results
Nanoparticle size: 70–98 nm (optimized for brain targeting)
Preserved exosome morphology after siRNA loading
Significant STAT3 downregulation (mRNA & protein levels)
Reduced tumor cell proliferation
Increased apoptosis
Decreased tumor volume in vivo
Extended survival in treated mice
No significant cytotoxicity observed
The second siRNA sequence demonstrated superior silencing efficiency and therapeutic performance.
🚀 Advantages of the NLP-EXOSOME Platform
✔ Enhanced siRNA stability
✔ Improved cellular uptake
✔ Reduced aggregation
✔ High biocompatibility
✔ Potential BBB penetration
✔ Targeted gene silencing with minimal toxicity
The hybrid design leverages the natural targeting ability of exosomes and the structural stability of lipid nanoparticles.
🏁 Conclusion
The NLP-EXOSOME COMPLEX delivering STAT3-targeted siRNA significantly inhibited glioblastoma progression and improved survival in a mouse model. This advanced nano-biotechnology platform represents a promising next-generation strategy for targeted gene therapy in brain cancer.
Further optimization and clinical evaluation are required for translation into human therapy.
📄 Full Article Reference
Title: Exosome Enveloped by Nano Lipid Particle a New Model forSignal Transducer and Activator of Transcription 3 SilencerRibonucleic Acid Delivery System to a Glioblastoma Mice Model
Journal: Cancers, 2025, 17(10), 1648
DOI: https://doi.org/10.3390/cancers17101648
